HETEROCONJUGATE VACCINES AGAINST HERPES SIMPLEX VIRUS

单纯疱疹病毒异源结合疫苗

• 批准号: 6373837
• 负责人: Daniel Hill Zimmerman
• 金额: $ 38.51万
• 依托单位: CEL-SCI CORPORATION
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-01 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6373837
• 关键词: Herpesviridae vaccine; T lymphocyte; glycoproteins; guinea pigs; herpes simplex virus 1; immunity; immunoconjugates; laboratory mouse; ligands; peptides; synthetic vaccines; vaccine development; virus antigen; virus protein

The primary goal of this program is the development of L.E.A.P.S.(TM) heteroconjugate peptide vaccines against herpes simplex virus) to prevent or treat human infection. The heteroconjugate vaccines are constructed of peptides which contain defined T cell epitopes and peptides which are predicted to bind to T cells or antigen presenting cells. The T cell epitopes that are being used are from the ICP27, glycoprotein B, and glycoprotein D of HSV-1. Our Phase I studies proved the principle behind this new technology by showing that incorporation of a viral peptide epitope into a L.E.A.P.S. construct based vaccine can enhance and define the type of immune response which is elicited to promote the development of protective and not detrimental immune responses. A L.E.A.P.S. vaccine can then be formulation with LEAPS constructs assembled with adjuvants to produce defined immune responses to defined epitopes. The major goal of the Phase II studies will be to optimize the vaccine formulation with respect to L.E.A.P.S. peptide (or mixture), the adjuvant and other components to allow progression to human trials. In addition, we will study the mechanism of action by which the L.E.A.P.S. peptide potentiates the immune response. The HSV vaccines are also prototypes for the development of heteroconjugate vaccine to treat or prevent disease caused by other infectious agents. The ultimate goal of our study will be to develop sufficient data to allow progression to human trials. PROPOSED COMMERCIAL APPLICATION: Heteroconjugate peptide vaccines use proprietary new technology called L.E.A.P.S. (Ligand Epitope Antigen Presentation System) to provide treatment and/or prophlysis against herpes simplex virus (HSV) infection and disease. HSV is a common oral pathogen and sexually transmitted disease which also causes serious disease. An estimated 40 to 60 million Americans are infected with HSV with approximately 600,000 new cases occurring per year. The HSV vaccine will be prototypes for the development of heteroconjugate vaccines to treat or prevent disease by other infectious agents.

该程序的主要目标是开发L.E.A.P.S.（TM）杂偶联肽疫苗针对单纯疱疹病毒），以预防或治疗人类感染。 杂共轭疫苗是由含有定义的T细胞表位和肽的肽构成的，这些肽被预测与T细胞或抗原呈递细胞结合。所使用的T细胞表位来自HSV-1的ICP27，糖蛋白B和糖蛋白D。我们的第一阶段研究证明了这项新技术背后的原理，表明将病毒肽表位纳入L.E.A.P.S.基于构造的疫苗可以增强和定义免疫反应的类型，该免疫反应的类型可促进保护性而不是有害免疫反应的发展。 L.E.A.P.S.然后，可以使用与佐剂组装的飞跃构建体制定疫苗，以产生对定义表位的定义免疫反应。第二阶段研究的主要目标是优化有关L.E.A.P.S.的疫苗配方。肽（或混合物），佐剂和其他成分，以允许进展为人类试验。 此外，我们将研究L.E.A.P.S.的作用机理。肽增强免疫反应。 HSV疫苗也是用于开发杂联疫苗的原型原型，以治疗或预防其他感染剂引起的疾病。我们研究的最终目标是制定足够的数据以允许进展为人类试验。拟议的商业应用程序：杂轭肽疫苗使用专有的新技术，称为L.E.A.P.S. （配体表位抗原表现系统）以针对单纯疱疹病毒（HSV）感染和疾病提供治疗和/或先知。 HSV是一种常见的口腔病原体和性传播疾病，也会引起严重的疾病。估计有40至6000万美国人感染了HSV，每年发生了大约60万例新病例。 HSV疫苗将是开发异构疫苗以治疗或预防其他感染剂疾病的原型原型。